Main Menu
MSAA
  • Toll-Free Helpline Call Us Toll Free (800) 532-7667 Search
  • Get MS Updates
  • Información en Español
  • Donate
  • Skip main navigation
MSAA logo
  • MS Information
    • MS Overview & Glossary
    • Newly Diagnosed
    • Symptoms
    • Treatments
    • COVID-19 and MS
    • Patient Support Programs
    • Clinical Trials Search
    • Publications
    • Latest News from MSAA
    • Videos and Webinars
    • Podcasts from MSAA
    • Toll-free Helpline & Chat
    • Información en Español
    • MS FAQs and Glossary
  • How MSAA Can Help
    • Toll-free Helpline & Chat
    • Publications
    • Videos and Webinars
    • Cooling Products
    • Equipment Products
    • MRI Access Program
    • Educational Programs
    • Shared Decision-Making Tools
    • Overall Wellness
    • Online Aquatic Center
    • FAQs
  • Living with MS
    • My MSAA Community
    • MS Conversations Blog
    • Multiple Sclerosis Implementation Network™ (MSIN™)
    • My MS Journey
    • My MS Manager™ Mobile App
    • MS Relapse Resource Center
    • Overall Wellness
    • Online Aquatic Center
    • Educational Programs
  • Donate
    • Make A Donation
    • Honor and Memorial Donations
    • Become a Monthly Improver
    • Planned Giving
    • Other Ways to Give
      • Donor-Advised Funds
      • Vehicle Donation
      • Matching Gifts
      • Shop & Support MSAA
    • Donation FAQs
  • Get Involved
    • Special Events
    • Art Showcase
    • Do-It-Yourself Fundraiser
    • Multiple Sclerosis Implementation Network™ (MSIN™)
    • Partnerships
    • Volunteer With MSAA
    • FAQ
  • Calendar
  • About MSAA
    • Mission and Overview
    • MS Awareness Month
    • MSAA Achievements
    • Contact Us
    • Board of Directors
    • Healthcare Advisory Council
    • African American Advisory Board
    • Hispanic/Latinx Advisory Board
    • MSAA Strategic Plan
    • Navigating MS
    • MS Coalition
    • Annual Report
    • Financial Information
  • Search
  • Home
  • Gilenya®
Back to Treatment Guide

Gilenya®

fingolimod, FTY720

Quick Facts

Gilenya, a S1P-receptor modulator, traps certain T and B cells in the lymph nodes and prevents them from attacking the central nervous system.

Capsule taken orally

Once per day; 0.5 mg capsule for adults

In pediatric patients 10 years of age and older weighing less than or equal to 40 kg, the recommended dosage is 0.25 mg orally once daily

Relapsing forms of multiple sclerosis in adults and children ages 10 and older, including clinically isolated syndrome, relapsing-remitting MS, and active secondary-progressive MS

Potential Benefit:

  • 48-54% reduction in relapses compared to placebo over 2 years. 41 and 52% reduction in relapses vs. Copaxone and Avonex, respectively
  • New or enlarging T2 lesions were reduced 74% and T1 contrast-enhancing lesions reduced 82% on Gilenya vs placebo in 2 year trial.
  • 30% reduction in 3-month confirmed disability progression in a 2 year trial
  • Reduction in brain volume loss 33-38% compared to placebo over 2 years

 

Common Potential Side Effects

Liver function test abnormalities, high blood pressure, respiratory infections.

Prescription Assistance:

Gilenya Go Program >

For assistance finding additional resources that might help cover the costs of your prescription, contact MSAA.


NEW FORMULATION OF FINGOLIMOD

Tascenso ODT® (fingolimod)

This is the first orally disintegrating version of fingolimod to be approved by the FDA. This is the same medication that is found with the brand name of Gilenya®, but rather than a solid pill that needs to be swallowed, Tascenso ODT is given by a pill that immediately dissolves on the tongue and does not require water. Clinical data shows that it has the same efficacy (effectiveness), safety, and purity as the original medication.

This new formulation became available in early 2023. For more information, the Cycle Vita patient-support team may be contacted by calling 1-888-360-VITA (1-888-360- 8482) or visiting www.cyclevita.life.


Hear from the Expert
Barry A. Singer, MD
Director and Founder, The MS Center for Innovations in Care,
Associate Professor of Clinical Neurology, Washington University
Barry A. Singer, MD
“It’s really important to me that I spend some time getting to know my patients in order to pick the right treatment.”

DRUGMAKER

Novartis

HOW Gilenya® WORKS

Gilenya® traps lymphocytes, a type of white blood cell, in the lymph nodes to keep them out of the brain and spinal cord. Gilenya may also have direct effects on cells in the central nervous system as well. Like Mayzent®, Zeposia® and Ponvory®, Gilenya® is a sphingosine 1-phosphate (S1P) receptor modulator.

FDA-Approved

Gilenya, FDA-approved in 2010, is indicated for relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary-progressive disease, in adults and children 10 years of age and older.

Potential Side Effects

Headache, flu, diarrhea, back pain, respiratory infections, abnormal liver tests and cough.

Possible adverse events include a reduction in heart rate (dose-related and transient); infrequent transient atrioventricular (AV) conduction block of the heart; increase in blood pressure; macular edema (swelling behind the eye); elevation of liver enzymes; and a slight increase in respiratory infections (including bronchitis). Rare serious infections include Progressive multifocal leukoencephalopathy (PML), a rare brain infection that usually leads to death or severe disability over a period of weeks or months, and fungal meningitis.

OTHER KEY INFORMATION

Testing completed prior to starting Gilenya® includes:

  • Baseline ECG.
  • Eye exam.
  • Blood tests including liver test, blood count and varicella (chickenpox) antibodies.
  • 6-hour monitoring of heart rate and blood pressure with first dose.

Patient advocates talk about
their treatment experience

  • Kristie Salerno Kent
    MS Advocate, Patient Advocacy Consultant
    Kristie Salerno Kent
    “I have had situations where treatments aren’t approved at first. My doctors, nurses, they actually go to bat for me and made it happen.”
  • Azure Antoinette
    MS Advocate
    Azure Antoinette
    "I will be undergoing my first disease-modifying therapy to help treat multiple sclerosis in my body and while I’m very nervous, I am equally as excited and looking forward to the positive effects of how I will feel physically, and mentally, and emotionally."
  • Damian Washington
    MS Advocate
    Damian Washington
    “Nobody’s going to be looking out for your best interests better than you.”
  • Cathy Chester
    MS Advocate
    Cathy Chester
    “I think it’s really important to talk about how to age with this illness.”
  • Lauren Hutton-Work
    MS Advocate
    Lauren Hutton-Work
    “Just because you have this disease does not mean that your work life should be awkward or uncomfortable.”
  • Chernise Joseph
    MS Advocate
    Chernise Joseph
    “My first neurologist was a frontline neurologist, he wasn’t an MS specialist.”
  • Julian Gamboa
    MS Advocate
    Julian Gamboa
    “If you’re newly diagnosed with multiple sclerosis remember it’s always okay to get a second opinion.”
  • Lauren and Sam Alcorn
    MS Advocates
    Lauren and Sam Alcorn
    “Our future is uncertain and we have to enjoy each other and love each other in the present.”
  • Shawn Feliciano
    MS Advocate
    Shawn Feliciano
    “I want to know what medications might work best for someone who’s Hispanic.”
  • Darlene Feigen
    MS Advocate
    Darlene Feigen
    “The sooner you get on a therapy the better it is in the long run.”
  • Birgit Bauer
    MS Advocate
    Birgit Bauer
    “At the end of the appointment you should have an answer to the most important questions.”
  • Ellen Tutton
    MS Advocate
    Ellen Tutton
    “I looked up all the different disease-modifying therapies and compared them to my lifestyle.”
  • Victoria Marie Reese
    MS Advocate
    Victoria Marie Reese
    “I’m trying to show my daughter that taking care of yourself is cool.”
    • MSAA logo
    • (800) 532-7667
    • msaa@mymsaa.org
    • MSAA is a 501(C)(3) nonprofit registered in the US under EIN: 22-1912812.Copyright ©2025 Multiple Sclerosis Association of America.Reproduction of material from any mymsaa.org pages without written permission is strictly prohibited.
    • GET EMAIL UPDATES
    • Privacy Policy and Terms of Use
    • Donor Privacy Policy
    • Financial Information
    • Información en Español
    • Contact Us
    • GET SMS UPDATES:
      Text
      MSAA to 75101

       
      Why sign up?
      You’ll get important MS-related news, crucial updates about our programs, and easy ways to support the MS community right from your phone.
       
      By participating, you agree to the terms and privacy policy for recurring autodialed campaign & donation messages from MSAA to the phone number you provide. No consent required to buy. Message and data rates may apply.
    • Guidestar Logo
    • Charity Navigator
    • America's Charities
    • Facebook
    • Twitter
    • Instagram
    • Tik Tok
    • Pinterest
    • YouTube
    • LinkedIn
    • ESSENTIAL
    • Accessibility Statement

Oct 2, 2023 @ 2:55 pm

×